Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice

Combined inhibition of vascular endothelial growth factor receptor (VEGFR) and the programmed cell death protein 1 (PD-1) pathways has shown efficacy in multiple cancers; however, the clinical outcomes show limited benefits and the unmet clinical needs still remain and require improvement in efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jia-Shiong, Hsieh, Yi-Chien, Chou, Cheng-Han, Wu, Yi-Hong, Yang, Mu-Hsuan, Chu, Sz-Hao, Chao, Ye-Su, Chen, Chia-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504159/
https://www.ncbi.nlm.nih.gov/pubmed/36142591
http://dx.doi.org/10.3390/ijms231810677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504159/
https://www.ncbi.nlm.nih.gov/pubmed/36142591
http://dx.doi.org/10.3390/ijms231810677

Ejemplares similares